DEVELOPMENT PIPELINE

We are leveraging our proprietary SNIPRx platform to discover, validate and build a robust clinical and pre-clinical pipeline of SL-based oncology therapeutics.

Development Pipeline

Program
Tumor Lesion
  • Discovery
  • IND-Enabling
  • Ph 1/2
  • Pivotal
Rights

Camonsertib
ATR Inhibitor

ATM + 16 lesions
  • Ph 1/2
TAPISTRY
  • Ph 1/2
Morpheus-Lung
  • Ph 1/2
TRESR: Monotherapy
  • Ph 1/2
TRESR: Mono + PARP (talazoparib) Combo
  • Ph 1/2
ATTACC: PARP (olaparib/niraparib) Combo
  • Ph 1/2
TRESR: Gemcitabine Combo
repare logo small

Lunresertib
PKMYT1 Inhibitor

CCNE1,
FBXW7 + others
  • Ph 1/2
CCTG ISTs
  • Ph 1/2
MYTHIC: Monotherapy
  • Ph 1/2
MAGNETIC: Gemcitabine Combo
  • Ph 1/2
MINOTAUR: FOLFIRI Combo
  • Ph 1/2
Carboplatin/paclitaxel Combo IST
repare logo small

RP-1664
Undisclosed

Undisclosed
  • Disc.
repare logo small

RP-3467
Polθ Inhibitor

BRCA1/2 + others
  • Disc.
repare logo small

Discovery Program
Multiple Targets

Undisclosed
  • Disc.
repare logo small

Discovery Program
Multiple Targets

Undisclosed
  • Disc.
repare logo small
Camonsertib
Targets
ATR Inhibitor
Tumor Lesion
ATM + 16 lesions
Clinical Trial
TAPISTRY
Progress
Phase 1/2
Clinical Trial
Morpheus-Lung
Progress
Phase 1/2
Clinical Trial
TRESR: Monotherapy
Progress
Phase 1/2
Clinical Trial
TRESR: Mono + PARP (talazoparib) Combo
Progress
Phase 1/2
Clinical Trial
ATTACC: PARP (olaparib/niraparib) Combo
Progress
Phase 1/2
Clinical Trial
TRESR: Gemcitabine Combo
Progress
Phase 1/2
Rights
Roche
Repare
Lunresertib
Targets
PKMYT1 Inhibitor
Tumor Lesion
CCNE1,
FBXW7 + others
Clinical Trial
CCTG ISTs
Progress
Phase 1/2
Clinical Trial
MYTHIC: Monotherapy
Progress
Phase 1/2
Clinical Trial
MAGNETIC: Gemcitabine Combo
Progress
Phase 1/2
Clinical Trial
MINOTAUR: FOLFIRI Combo
Progress
Phase 1/2
Clinical Trial
Carboplatin/paclitaxel Combo IST
Progress
Phase 1/2
Rights
Repare
RP-1664
Targets
Undisclosed
Tumor Lesion
Undisclosed
Progress
Discovery
Rights
Repare
RP-3467
Targets
Polθ Inhibitor
Tumor Lesion
BRCA1/2 + others
Progress
Discovery
Rights
Repare
Discovery Program
Targets
Multiple Targets
Tumor Lesion
Undisclosed
Progress
Discovery
Rights
Repare
Discovery Program
Targets
Multiple Targets
Tumor Lesion
Undisclosed
Progress
Discovery
Rights
Bristol Myers Squibb

Learn about our collection of ongoing clinical trials.

View Clinical Trials